São Paulo, Brazil
São Paulo, Brazil

Time filter

Source Type

News Article | December 17, 2016
Site: www.PR.com

Receive press releases from MedAware Systems, Inc.: By Email Broomfield, CO, December 17, 2016 --( Dr. Nichol is a renowned surgeon and researcher. He is certified by the American Board of Surgery in General Surgery and Pediatric Surgery. Dr. Nichol specializes in minimally invasive surgery, including pediatric general surgery, pediatric thoracic surgery, minimally invasive pediatric surgery, and pediatric trauma surgery. Dr. Nichol served as a principal investigator, or co-investigator, on numerous NIH funded research grants and is widely published in leading peer reviewed journals. His research is focused on pediatric nutrition and caring for children with congenital anomalies of the intestine. “We are pleased to announce that Dr. Nichol is joining us as our Chief Medical Officer,” says Michael Willis, Chief Executive Officer for MedAware Systems. “Dr. Nichol has been, and remains, a passionate thought leader on the critical role medical evidence plays in creating optimal healthcare organizations. His ability to effectively connect and communicate with diverse segments in the healthcare industry will be instrumental as MedAware Systems expands its unique and powerful data services for Clinicians, Patients, Pharma and Medical Device Companies, and Payers,” he adds. Dr. Nichol is a graduate of the Washington University School of Medicine, St. Louis, MO. Prior to joining the faculty at the University of Wisconsin School of Medicine and Public Health, he was an Assistant Professor and Research Fellow at Children’s Health Research Center, University of Utah, and a Staff Surgeon and Pediatric Surgery Fellow at Children's Hospital of Philadelphia, Philadelphia, PA. About MedAware Systems, Inc. MedAware Systems, Inc. disrupts the health informatics industry by forever changing the way physicians, researchers, payers and consumers derive usable, accurate evidence from published clinical trials research. The Company is continuously populating its industry leading database with all available medical research information. These data are extracted, normalized and standardized using the Companies patent-pending software and methodologies to provide highly accurate search and retrieval of evidence-based medical treatments and outcomes. With data precisely filtered by patient profile and disease profile, customers receive the most comprehensive, accurate, and granular meta-analysis of medical research data available today. Broomfield, CO, December 17, 2016 --( PR.com )-- MedAware Systems, Inc. announced today that Dr. Peter Nichol has joined the Company as its Chief Medical Officer. Dr. Nichol has served as Chair of the Company’s Scientific Advisory Board since 2015.Dr. Nichol is a renowned surgeon and researcher. He is certified by the American Board of Surgery in General Surgery and Pediatric Surgery. Dr. Nichol specializes in minimally invasive surgery, including pediatric general surgery, pediatric thoracic surgery, minimally invasive pediatric surgery, and pediatric trauma surgery.Dr. Nichol served as a principal investigator, or co-investigator, on numerous NIH funded research grants and is widely published in leading peer reviewed journals. His research is focused on pediatric nutrition and caring for children with congenital anomalies of the intestine.“We are pleased to announce that Dr. Nichol is joining us as our Chief Medical Officer,” says Michael Willis, Chief Executive Officer for MedAware Systems. “Dr. Nichol has been, and remains, a passionate thought leader on the critical role medical evidence plays in creating optimal healthcare organizations. His ability to effectively connect and communicate with diverse segments in the healthcare industry will be instrumental as MedAware Systems expands its unique and powerful data services for Clinicians, Patients, Pharma and Medical Device Companies, and Payers,” he adds.Dr. Nichol is a graduate of the Washington University School of Medicine, St. Louis, MO. Prior to joining the faculty at the University of Wisconsin School of Medicine and Public Health, he was an Assistant Professor and Research Fellow at Children’s Health Research Center, University of Utah, and a Staff Surgeon and Pediatric Surgery Fellow at Children's Hospital of Philadelphia, Philadelphia, PA.About MedAware Systems, Inc.MedAware Systems, Inc. disrupts the health informatics industry by forever changing the way physicians, researchers, payers and consumers derive usable, accurate evidence from published clinical trials research. The Company is continuously populating its industry leading database with all available medical research information. These data are extracted, normalized and standardized using the Companies patent-pending software and methodologies to provide highly accurate search and retrieval of evidence-based medical treatments and outcomes. With data precisely filtered by patient profile and disease profile, customers receive the most comprehensive, accurate, and granular meta-analysis of medical research data available today. Click here to view the list of recent Press Releases from MedAware Systems, Inc.


According to Stratistics MRC, the Global Minimally Invasive Surgical Instruments market is expected to grow from $9.34 billion in 2015 to reach $21.23 billion by 2022 with a CAGR of 12.4%. Better performance of minimally invasive surgeries as compared to traditional open surgeries is the main driving factor fueling the market growth. Moreover, rising chronic disorders as well surgeries and innovative technological improvements are the factors boosting the market growth. On the other hand, lack of skilled surgeons to adopt new technologies and unstable regulations in the medical industries are restricting the market growth. Access the complete report at: http://www.strategymrc.com/report/minimally-invasive-surgical-instruments-market The orthopedic surgery segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to increasing geriatric population coupled with bone disorders and rising spine injuries. Among all product types, the handheld instruments segment dominates the global market. This is due to vast usage of the handheld instrument in most of all minimally invasive surgeries. North America is leading the global market with a higher CAGR. Asia Pacific is projected to grow at a faster pace during the forecast period. Increasing government spending, growing numerous surgeries, increasing adoption of latest surgical instruments are the factors contributing to the North America market growth. Some of the key players in global minimally invasive surgical instruments market include Davol, Inc., Conmed Corporation, Aesculap, Inc. (Subsidiary of B. Braun Melsungen AG), Aesculap, Inc., Ethicon Endo-Surgery, Inc., Encision, Inc., Acmi Circon, Abbott Laboratories , Ethicon, Inc. (Subsidiary of Johnson & Johnson), Karl Storz Endoscopy-American, Inc., Smith & Nephew PLC, Olympus Corp. of America, Microline Surgicals, Inc. (Subsidiary of Hoya Corporation), Zimmer Biomet Holdings, Inc., Stryker Corporation, and Medtronic PLC. Request for a sample at: http://www.strategymrc.com/report/minimally-invasive-surgical-instruments-market Products Covered: • Cutter Instruments o Rasps o Trocars o Other Cutter Instruments • Inflation Systems o Balloon Inflation Devices o Balloons o Other Inflation Systems • Auxiliary Instruments o Cannulas o Clamps o Closure Devices o Staplers • Handheld Instruments o Dilators o Forceps and Spatulas o Graspers o Retractors o Stents o Sutures o Visualizing scopes o Other Products • Electrosurgical Instruments o Electrocautery Devices o Electrosurgical Generators o Electrosurgical Instruments • Guiding Devices o Guidewires o Guiding Catheters End Users Covered: • Academic and Research Institutes • Government Hospitals • Private Hospitals and Surgical Clinics Applications Covered: • Gastrointestinal surgery • Cosmetic/Bariatric Surgery • Cardiothoracic Surgery • Vascular Surgery • Urological Surgery • Orthopedic Surgery • Gynecological Surgery • Other Applications o ENT/Respiratory Surgery o Neurological Surgery o Dental Surgery o Pediatric Surgery Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | February 28, 2017
Site: www.marketwired.com

Kids playing GoNoodle scored 23 percent better in reading skills; 13 percent improvement in normal weight (measured by BMI) among kids playing GoNoodle in Ft. Worth, TX FORT WORTH, TX--(Marketwired - February 28, 2017) - The Center for Children's Health led by Cook Children's announced today the results from two studies on the impact of GoNoodle's online movement videos and games in greater Ft. Worth, Texas. One study shows students who play GoNoodle videos at school had 23 percent greater growth in reading knowledge and skills when compared to those that did not play GoNoodle. Another study shows an average 13 percent improvement in childhood normal weight (as measured by body mass index or BMI) during a three-year period for elementary-age students who attend schools at independent school districts using GoNoodle. "This is the most powerful evidence to date showing that classroom physical activity dramatically improves health and academic performance in students," said Larry Tubb, Senior Vice President for Cook Children's. For the past three years, Cook Children's has sponsored GoNoodle for elementary schools in greater Ft. Worth. Based on the health and academic impact of GoNoodle, and feedback from teachers about the value it brings to classrooms, Cook Children's has expanded its sponsorship of GoNoodle, making it available to more than 15,000 teachers and 300,000 students in public, private and charter schools across the six county region. Since 2009, parents have been providing their children's height and weight measurements to the Center for Children's Health as part of broader study of children's health issues in Denton, Hood, Johnson, Parker, Tarrant, and Wise counties. The data includes 8,287 children from age 2 to 14. In analyzing this data, children 6-12 years old on average showed a 13.2 percent improvement in normal weight, as measured by BMI and adjusted for natural changes based on child's age. Individual age cohort improvements ranged from 1.9 percent to 17.5 percent improvement during the three-year period between 2012-2015. This time period correlates with the same time periods of GoNoodle's use in 521 schools across the six county area in which 124,829 elementary students (43 percent of eligible elementary students between 2012-2015) played GoNoodle each month at school. During the 2014-15 school year, Ft. Worth area students earned 34.7 million minutes of physical activity on GoNoodle. "The number of elementary-aged children actively using GoNoodle is large enough, at 43 percent, for changes in their BMI to be reflected in the data about the entire population," said Larry Tubb, Senior Vice President for Cook Children's. "While there are other good community efforts towards improving childhood health, there are no other initiatives that achieve the reach, frequency of use, and measurable minutes provided by GoNoodle in our six county service area." During the 2015-16 school year, assessments from over 1,000 fourth and fifth grade students from 26 Fort Worth area schools were evaluated. The standardized assessments of reading knowledge and skills of students who used GoNoodle (treatment group) were compared to the reading knowledge and skills of students who did not use GoNoodle (control group). The pre and post state standardized assessments of reading skills were used as the independent measures of students' skills. Fourth and fifth grade classrooms that used GoNoodle at least twice per week throughout the 2015-2016 school year were included in the treatment group. The study was conducted by SEG Measurement, an independent research organization. "Students using GoNoodle showed significantly greater growth in reading scores on the state assessment," according to Scott Elliot, President of SEG Measurement. "Students using GoNoodle performed 23 percent better in reading than students who did not use GoNoodle. This study confirms and expands on prior studies that support the effectiveness of GoNoodle. Students perform better on standardized assessments and teachers report the product to be very effective in meeting their needs." "Short bursts of in-classroom physical activity with GoNoodle yield big results for schools. Across the country we are seeing that kids perform better academically, and they are growing up healthier," said Scott McQuigg, CEO & co-founder of GoNoodle. "These studies are strong evidence that getting students moving throughout the school day fuels kids' bodies and brains." More information on each of these studies can be found at www.centerforchildrenshealth.org. Cook Children's Health Care System embraces an inspiring Promise -- to improve the health of every child in our region through the prevention and treatment of illness, disease and injury. Based in Fort Worth, Texas, we're proud of our long and rich tradition of serving our community. Our not-for-profit organization is comprised of eight companies, including our Medical Center, Physician Network, Home Health Company, Northeast Hospital, Pediatric Surgery Center, Health Plan, Health Services Inc., and Health Foundation. With more than 60 primary, specialty and urgent care locations throughout Texas, families can access our top-ranked specialty programs and network of services to meet the unique needs of their child. For nearly 100 years we've worked to improve the health of children from across our primary service area of Denton, Hood, Johnson, Parker, Tarrant and Wise counties. We combine the art of caring with leading technology and extraordinary collaboration to provide exceptional care for every child. This has earned Cook Children's a strong, far-reaching reputation with patients traveling from around the country and the globe to receive life-saving pediatric care. GoNoodle (launched in 2013), gets kids moving to be their smartest, strongest, bravest, silliest, bestest selves. Short, interactive movement videos and games make it awesomely simple and fun to incorporate movement into every part of the day with dancing, stretching, running and even mindfulness activities. At school, teachers use GoNoodle to keep students energized, engaged, and active inside the classroom. At home, GoNoodle turns screen time into active time, so families can have fun and get moving together. Currently, more than 12 million kids and over 600,000 teachers worldwide use GoNoodle each month. GoNoodle is used in 80% of U.S. public elementary schools in all 50 states and in schools around the world in 185 countries. Nearly 1.5 million families use GoNoodle at home either through the website or the recently released iOS app. Learn more at www.gonoodle.com. SEG Measurement is an independent provider of research and assessment development services. We believe that students have a right to an education grounded in research-proven solutions. SEG Measurement is located in New Hope, Pennsylvania, between New York City and Philadelphia. Learn more at www.segmeasurement.com.


News Article | November 17, 2016
Site: www.prweb.com

The Mount Sinai Hospital has been recognized for meritorious outcomes for surgical patient care for the third consecutive year by The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®), one of 60 ACS NSQIP participating hospitals in the nation to achieve this recognition. As a participant in ACS NSQIP, The Mount Sinai Hospital is required to track the outcomes of inpatient and outpatient surgical procedures and collect data that directs patient safety and the quality of surgical care improvements. The Mount Sinai Hospital is one of only 18 hospitals to have received meritorious status two years in a row, and one of only five hospitals to receive the status in three consecutive years, out of 615 domestic and international hospitals that were analyzed for the most current outcomes measures. “Mount Sinai is honored to once again receive this distinction, which clearly positions our surgeons as industry leaders,” said Michael L. Marin, MD, Professor of Surgery at Icahn School of Medicine at Mount Sinai and System Chair of Surgery at Mount Sinai Health System. “Our faculty provide the highest quality surgical care for patients of all ages and are dedicated to advancing treatments and outcomes through innovative research and state-of-the-art technology. “This recognition is only possible through the outstanding efforts of our surgeons and the detailed precision of our Surgical Outcomes and Quality Improvement (SOQI) team,” said Celia Divino, MD, Professor of Surgery at Icahn School of Medicine at Mount Sinai, Chief of the Aufses Division of General Surgery at Mount Sinai Health System, and ACS NSQIP Surgeon Champion for The Mount Sinai Hospital. “The SOQI team continuously abstracts longitudinal data to ensure optimal performance, and pinpoints opportunities to innovate new standards in patient care.” The ACS NSQIP recognition program commends a select group of hospitals for achieving a composite meritorious outcome related to patient management in eight clinical areas: mortality, unplanned intubation, ventilator > 48 hours, renal failure, cardiac incidents (cardiac arrest and myocardial infarction); respiratory (pneumonia); SSI (surgical site infections-superficial and deep incisional and organ-space SSIs); or urinary tract infection. The 60 hospitals commended achieved the distinction based on their outstanding composite quality score across the eight areas listed above. Risk-adjusted data from the July 2016 ACS NSQIP Semiannual Report, which presents data from the 2015 calendar year, were used to determine which hospitals demonstrated meritorious outcomes. ACS NSQIP is the only nationally validated quality improvement program that measures and enhances the care of surgical patients. This program measures the actual surgical results 30 days postoperatively as well as risk adjusts patient characteristics to compensate for differences among patient populations and acuity levels. The goal of ACS NSQIP is to reduce surgical morbidity (infection or illness related to a surgical procedure) and surgical mortality (death related to a surgical procedure) and to provide a firm foundation for surgeons to apply what is known as the “best scientific evidence” to the practice of surgery. Furthermore, when adverse effects from surgical procedures are reduced and/or eliminated, a reduction in health care costs follows. ACS NSQIP is a major program of the American College of Surgeons and is currently used in over 770 adult and pediatric hospitals. The Surgical Outcomes and Quality Improvement (SOQI) office is a centralized group within the Department of Surgery that focuses on improving clinical outcomes and patient experience through dedicated data collection/analysis, innovative process engineering, and targeted quality improvement projects. The office monitors a broad range of surgical procedures including general surgery, vascular, plastics, surgical oncology, colorectal and pediatrics. The department’s relatively high case volume fosters the ability to impact a large population of surgical candidates and implement improvements that are tailored to specific patients’ needs. The Ruth J. & Maxwell Hauser and Harriet & Arthur H. Aufses, Jr., MD, Department of Surgery at The Mount Sinai Hospital is nationally recognized for its excellence in surgical care for a broad spectrum of specialties. The Department includes the Divisions of Colon and Rectal Surgery, General Surgery, Metabolic Surgery, Endocrine and Minimally Invasive Surgery, Pediatric Surgery, Plastic and Reconstructive Surgery, the Surgical Intensive Care Unit, Surgical Oncology and Vascular and Endovascular Surgery. The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and to improve the care of the surgical patient. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 78,000 members and it is the largest organization of surgeons in the world. About the Mount Sinai Health System The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is on the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals. Mount Sinai Health System was ranked number 3 in the Top Ten hospitals and health systems in DiversityInc in 2016". For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.


News Article | November 3, 2016
Site: www.eurekalert.org

HOUSTON - (Nov. 3, 2016) - Results of a cellular therapy clinical trial for traumatic brain injury (TBI) using a patient's own stem cells showed that the therapy appears to dampen the body's neuroinflammatory response to trauma and preserve brain tissue, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results, which also confirmed safety and feasibility as cited in earlier studies, were published online Nov. 1 in the journal STEM CELLS. "The data derived from this trial moves beyond just testing safety of this approach," said Charles S. Cox, Jr., M.D., principal investigator, the George and Cynthia Mitchell Distinguished Chair in Neurosciences at UTHealth, professor in the Department of Pediatric Surgery and co-director of the Memorial Hermann Red Duke Trauma Institute. "We now have a hint of a treatment effect that mirrors our pre-clinical work, and we are now pursuing this approach in a Phase 2b clinical trial sponsored by the Joint Warfighter Program within the U.S. Army Medical Research Acquisition Activity, as well as our ongoing Phase 2b pediatric severe TBI clinical trial - both using the same autologous cell therapy." Cox was recently awarded $6.8 million in funding from the U.S. Department of Defense (DOD) for the Phase 2b study to assess the safety and efficacy - including whether there are structural improvements in the brain - of autologous stem cell therapy in adults with emergent traumatic brain injury. Memorial Hermann-Texas Medical Center is the site for the study. According to the Centers for Disease Control, 1.7 million Americans sustain a traumatic brain injury annually. Of those, 275,000 are hospitalized and 52,000 die. TBI is a contributing factor to a third of all injury-related deaths in the country. According to published research cited in the paper, more than 6.5 million patients are burdened by the physical, cognitive and psychosocial deficits associated with TBI, leading to an economic impact of approximately $60 billion. There are few current therapies to treat TBI. Critical care teams work to stabilize patients and surgery is sometimes necessary to remove or repair damaged blood vessels or tissue, as well as provide relief from swelling. To potentially open a new avenue of treatment, Cox has been researching cell therapy for neurological disease in pre-clinical and clinical trials for more than two decades. The new study builds on his previously published research showing that autologous stem cell therapy after TBI is safe and reduces the therapeutic intensity requirements of neurocritical care. The theory is that the stem cells work in the brain to alleviate the body's inflammatory response to the trauma. Researchers enrolled 25 patients in a dose-escalation format with five controls followed by five patients in each of three different doses followed by five more controls for a total of 25. Bone marrow harvesting, cell processing and re-infusion occurred within 48 hours after injury. Cellular processing was done at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at McGovern Medical School. Functional and neurocognitive outcomes were measured and correlated with imaging data including magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) of white brain matter. According to the authors, despite the treatment group having greater injury severity, there was structural preservation of critical regions of interest that correlated with functional outcomes and key inflammatory cytokines were down-regulated after bone marrow cell infusion. The study was funded by DOD grant W81XWH-11-1-0460, National Institutes of Health grant 2T32 GM 0879201-11, the Glassell Foundation Stem Cell Research Program and The Brown Foundation, Inc. Making the trial possible was a large team of co-investigators from McGovern Medical School Departments of Neurosurgery, Surgery, Neurology, Pediatrics, and Diagnostic and Interventional Imaging; The University of Texas MD Anderson Cancer Center Department of Pediatrics; and related clinical care teams. McGovern Medical School co-investigators were Robert A. Hetz, M.D.; George P. Liao, M.D.; Benjamin M. Aertker, M.D.; Linda Ewing-Cobbs, Ph.D.; Jenifer Juranek, Ph.D.; Sean I. Savitz, M.D.; Margaret L. Jackson, M.D.; Anna M. Romanowska-Pawliczek, Ph.D.; Fabio Triolo, Ph.D.; Pramod K. Dash, Ph.D.; Claudia Pedroza, Ph.D.; HuiMahn A. Choi, M.D.; John B. Holcomb, M.D; and Ryan S Kitagawa, M.D. Other co-investigators were Dean A. Lee, Ph.D., Nationwide Children's Hospital; Laura Worth, MD Anderson Cancer Center, M.D., Ph.D.; and Imoigele P. Aisiku, M.D., Brigham and Women's Hospital.


Cell therapy safe, effective in mitigating neuroinflammatory response and preserving brain tissue after TBI NEW YORK, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Cellvation, Inc., a clinical-stage biopharmaceutical company and majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ:FBIO) developing novel cell therapies for the treatment of traumatic brain injury ("TBI”), announced today data demonstrating a patient’s own stem cells may be safe and effective in diminishing neuroinflammatory response and preserving brain tissue in adults following severe TBI. Data from a Phase 1 study of Cellvation’s CEVA101, an autologous bone marrow-derived mononuclear cell therapy, were published online this month in the journal STEM CELLS. Researchers at The University of Texas Health Science Center at Houston (UTHealth) conducted the dose-escalation study in 25 adults with severe TBI and without signs of irreversible brain injury. Bone marrow harvest, cell processing and re-infusion occurred within 48 hours after injury. The bone marrow mononuclear cells were observed to be safe and well-tolerated, with no serious adverse events related to the harvest or infusion. Furthermore, investigators in the study found evidence of central nervous system structural preservation, consistent with data from a Phase 1 pediatric trial of Cellvation’s CEVA101, and the mitigation of inflammatory biomarkers following cell infusion. “The data derived from this trial moves beyond just testing safety of this approach,” said Charles S. Cox, Jr., M.D., principal investigator, the George and Cynthia Mitchell Distinguished Chair in Neurosciences at UTHealth, professor in the Department of Pediatric Surgery and co-director of the Memorial Hermann Red Duke Trauma Institute. “We now have a hint of a treatment effect that mirrors our pre-clinical work, and we are now pursuing this approach in a Phase 2b clinical trial sponsored by the Joint Warfighter Program within the U.S. Army Medical Research Acquisition Activity, as well as our ongoing Phase 2b pediatric severe TBI clinical trial – both using the same autologous cell therapy.” The Phase 1 study was supported by U.S. Department of Defense grant W81XWH-11-1-0460, National Institutes of Health grant 2T32 GM 0879201-11, the Glassell Foundation Stem Cell Research Program and The Brown Foundation, Inc. “To our knowledge, the STEM CELLS publication is the first reported clinical assessment of an IV-infused cell therapy for the treatment of severe TBI in adults. The data set is compelling and suggests that CEVA101 could be a safe and effective approach in the acute trauma setting,” said Frank Taffy, co-founder, interim CEO, President and a member of Cellvation’s Board of Directors. “We are thrilled to be working with UTHealth to advance this innovative program in a high-risk setting characterized by significant unmet medical need.” Charles S. Cox, Jr., M.D., and UTHealth have research-related financial interests in Fortress, including its subsidiary Cellvation. About Bone Marrow-Derived Stem Cells for the Treatment of Traumatic Brain Injury Traumatic brain injury (“TBI”) remains one of the greatest unsolved problems in clinical trauma care today. Cell-based therapy is distinguished from small molecule strategies by the pleiotropic mechanisms of action that have been determined in preclinical data and an excellent safety profile in early clinical trials. The mechanism of action appears to be related to down-regulation of neuroinflammatory response of the innate immune system. Proof of concept data have been generated by The University of Texas Health Science Center at Houston (UTHealth) using bone marrow mononuclear cells (BMMNCs) in both stroke and TBI. These data formed the foundation for Phase 1 and 2 clinical trials of Cellvation’s BMMNCs (CEVA101) in pediatric patients with severe TB and in adults with severe TBI. Cellvation also maintains rights to CEVA-D, a novel bioreactor that amplifies anti-inflammatory gene programs in adherent bone marrow-derived mesenchymal stromal cells without external gene transfection approaches. The utility of this approach has been confirmed using in vivo models of TBI. Development of this pipeline of cellular therapeutics represents an opportunity to fundamentally change the approach to TBI treatment. About The University of Texas Health Science Center at Houston Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in The UT System and the U.S. Gulf Coast region, UTHealth is home to schools of biomedical informatics, biomedical sciences, dentistry, nursing and public health and the John P. and Kathrine G. McGovern Medical School. UTHealth includes The University of Texas Harris County Psychiatric Center and a growing network of clinics throughout the region. The university’s primary teaching hospitals include Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann Hospital and Harris Health Lyndon B. Johnson Hospital. For more information, visit www.uth.edu. UTHealth is a leader in cell therapeutics for neurological injury and has developed novel approaches to the treatment of traumatic brain injury. McGovern Medical School at UTHealth is a collaborator with Memorial Hermann-Texas Medical Center in the Memorial Hermann Red Duke Trauma Institute and Memorial Hermann Mischer Neuroscience Institute. Memorial Hermann-TMC is one of the busiest Level 1 American College of Surgeons-verified Adult and Pediatric Trauma Centers in the country. About Cellvation Cellvation, Inc., is a clinical-stage biopharmaceutical company developing novel cellular therapeutics for the treatment of traumatic brain injury ("TBI”). Cellvation is currently advancing clinical-stage cell therapies in severe TBI: a Phase 2 study of CEVA101 in pediatric patients (ClinicalTrials.gov Identifier: NCT01851083), and a Phase 2 study of CEVA101 in adults (ClinicalTrials.gov Identifier: NCT02525432). These studies are supported by grants of approximately $10 million from the National Institutes of Health and the Department of Defense. Cellvation is also developing CEVA-D, a novel bioreactor that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation. Cellvation is a majority‐owned subsidiary of Fortress Biotech (NASDAQ:FBIO) and is based in New York City. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies.  Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ:NHLD), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.


Cellvation to Advance Three Programs Licensed from UTHealth Two Phase 2 Studies Supported by Approximately $10M in Secured Grant Funding NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc., (NASDAQ:FBIO) has formed a new subsidiary company, Cellvation, Inc., to develop novel therapies for the treatment of traumatic brain injury (“TBI”). Cellvation has entered into an agreement with The University of Texas Health Science Center at Houston (UTHealth) to secure exclusive worldwide rights to three programs for TBI, including two Phase 2 cell therapies. For the pediatric population, a randomized, multi-center, double-blind, placebo-controlled, Phase 2 study of autologous bone marrow-derived stem cells for the treatment of severe TBI is ongoing and will enroll up to 50 patients (ClinicalTrials.gov Identifier: NCT01851083). For adults, a soon-to-be-commenced, randomized, double-blind, placebo-controlled, Phase 2 study of autologous bone marrow-derived stem cells for the treatment of severe TBI will enroll up to 55 patients (ClinicalTrials.gov Identifier: NCT02525432). The Phase 2 studies are supported by secured grants of approximately $10 million from the National Institutes of Health and the Department of Defense. Cellvation plans to strategically supplement this grant funding to open additional clinical sites and accelerate study outcomes. According to the Centers for Disease Control and Prevention, TBI is a leading cause of death and disability in adults and children in the United States, contributing to almost one third of all injury-related mortalities. TBI results from a trauma or jolt to the head (or a penetrating head injury) that impacts normal brain function. TBIs range in severity from “mild” (a brief change in mental status or consciousness, often referred to as a concussion) to “severe” (an extended period of unconsciousness typically requiring hospitalization). Based on the National Hospital Discharge Survey, there were approximately 2.5 million TBIs in the United States in 2010, which resulted in more than 50,000 deaths and 280,000 hospitalizations. Injuries associated with TBI cost an estimated $76 billion annually in the United States. Cellvation also licensed rights from UTHealth to a next-generation bioreactor that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation. As Cellvation continues clinical development of its lead programs in the United States, it will explore early market entry in Japan under the recently revised Pharmaceutical Affairs Law, which provides for conditional approval of regenerative medicine products upon demonstration of safety and efficacy in early clinical studies. The Cellvation programs were developed by Dr. Charles Cox, George & Cynthia Mitchell Distinguished Chair in Neurosciences; Director, Children’s Regenerative Medicine, McGovern Medical School at the UTHealth Department of Pediatric Surgery; and Co-Director of the Memorial Hermann Red Duke Trauma Institute. Dr. Cox will serve as a key scientific advisor to the Company. “Cellular therapies are a highly promising strategy to mitigate the neuroinflammatory response to TBI that amplifies the initial injury,” said Dr. Cox. “Targeting this ‘secondary brain injury’ is designed to preserve injured tissue and ultimately improve outcomes. We are excited to work with the Cellvation team to advance these important programs.” Dr. Lindsay A. Rosenwald, Chairman and CEO of Fortress Biotech, stated, “We are pleased to enter into this collaboration with UTHealth and Dr. Charles Cox. TBI is associated with significant unmet medical need and a standard of care that hasn’t evolved much over the past two decades. Data generated by Dr. Cox and his team suggest a cell therapy could reduce further injury following a head trauma and improve long-term outcomes. We look forward to continuing development of these exciting therapies and delivering them to the bedside.” Fortress also announced the appointment of Frank Taffy as interim Chief Executive Officer, President and member of Cellvation’s Board of Directors. Mr. Taffy identified the Cellvation programs and co-founded the company. He has more than 15 years of experience in life sciences corporate development and operations. Mr. Taffy currently serves as President, Chief Executive Officer and member of the Board of Directors for Helocyte, Inc., a company he also co-founded that is focused on the development of novel immunotherapies for cancer and infectious disease. He previously held the positons of Head (Senior Director) of Business Affairs at Forest Laboratories (now Allergan) and Director of Corporate Development at Life Technologies (now Thermo Fisher Scientific), where he also held Board positions on behalf of the company. Mr. Taffy began his career as Counsel for Intellectual Property at Procter & Gamble. He holds a J.D. from Syracuse University College of Law and a B.A. in biochemistry from the University of North Texas. About Bone Marrow-Derived Stem Cells for the Treatment of Traumatic Brain Injury Traumatic brain injury (“TBI”) remains one of the greatest unsolved problems in clinical trauma care today. Cell-based therapy is distinguished from small molecule strategies by the pleiotropic mechanisms of action that have been determined in preclinical data and an excellent safety profile in early clinical trials. Proof of concept data have been developed using bone marrow mononuclear cells in both stroke and TBI, and these data formed the foundation for translation into Phase 1 and 2 clinical trials at UTHealth. The mechanism of action appears to be related to down-regulation of neuroinflammatory response of the innate immune system. Cellvation further licensed rights from UTHealth to a novel bioreactor that amplifies anti-inflammatory gene programs in adherent bone marrow derived mesenchymal stromal cells without external gene transfection approaches. The utility of this approach has been confirmed using in vivo models of TBI. Development of this pipeline of cellular therapeutics represents an opportunity to fundamentally change the approach to TBI treatment. About The University of Texas Health Science Center at Houston Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in The UT System and the U.S. Gulf Coast region, UTHealth is home to schools of biomedical informatics, biomedical sciences, dentistry, nursing and public health and the John P. and Kathrine G. McGovern Medical School. UTHealth includes The University of Texas Harris County Psychiatric Center and a growing network of clinics throughout the region. The university’s primary teaching hospitals include Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann Hospital and Harris Health Lyndon B. Johnson Hospital. For more information, visit www.uth.edu. UTHealth is a leader in cell therapeutics for neurological injury and has developed novel approaches to the treatment of traumatic brain injury. McGovern Medical School at UTHealth is a collaborator with Memorial Hermann-Texas Medical Center in the Memorial Hermann Red Duke Trauma Institute and Memorial Hermann Mischer Neuroscience Institute. Memorial Hermann-TMC is one of the busiest Level 1 American College of Surgeons-verified Adult and Pediatric Trauma Centers in the country. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes its products both within Fortress and through subsidiary companies, also known as Fortress Companies, and also develops other products relating to financial services through its affiliate, National Holdings Corporation (NASDAQ:NHLD). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensing, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.


News Article | February 27, 2017
Site: www.eurekalert.org

Aurora, Colo. (Feb. 27, 2017) - New research from Children's Hospital Colorado (Children's Colorado) focused on helmet safety and injury prevention among young skiers and snowboarders. The research found that children who wear a helmet while skiing or snowboarding sustain less severe head injuries and lower overall injury severity, compared to children who do not wear a helmet. The research was published in the Journal of Pediatric Surgery in February 2017. The research was led by Steven Moulton MD, medical director of the trauma program at Children's Colorado. The study analyzed 16 years of level I pediatric trauma center data from Children's Colorado and included children ages 3-17 years old who sustained an injury while skiing or snowboarding. In addition to proving the benefits of helmet use, Dr. Moulton found that young Colorado residents were nearly twice as likely to be wearing a helmet at the time of injury, compared to visitors from out-of-state. "Many Colorado parents may not view these findings as a surprise. It is imperative, however, that we broaden the conversation so that parents who encourage their children to ski or snowboard know that wearing a helmet is protective, but does not excuse recklessness," said Dr. Moulton. "Parents must teach their kids to enjoy snow sports within their own safety limits. Wearing a helmet lowers the risk of sustaining a serious head injury--but does not prevent other serious bodily injury." The full report is now available on the Journal of Pediatric Surgery website. Children's Hospital Colorado (Children's Colorado) has defined and delivered pediatric health care excellence for more than 100 years. Founded in 1908, Children's Colorado is a leading pediatric network entirely devoted to the health and well-being of children. Continually acknowledged as one of the nation's outstanding pediatric hospitals by U.S. News & World Report and ranked on its Best Children's Hospitals 2016-17 Honor Roll, Children's Colorado is known for both its nationally and internationally recognized medical, research, education and advocacy programs, as well as comprehensive everyday care for kids throughout Colorado and surrounding states. Children's Colorado is the winner of the 2015 American Hospital Association-McKesson Quest for Quality Prize, and is a 2013-2016 Most Wired hospital according to Hospitals & Health Networks magazine. Children's Colorado also is recognized for excellence in nursing from the American Nurses Credentialing Centers and has been designated a Magnet® hospital since 2005. The hospital's family-centered, collaborative approach combines the nation's top pediatric doctors, nurses and researchers to pioneer new approaches to pediatric medicine. With urgent, emergency and specialty care locations throughout Metro Denver and Southern Colorado, including its campus on the Anschutz Medical Campus, Children's Colorado provides a full spectrum of pediatric specialties. For more information, visit http://www. and connect with Children's Colorado on Facebook, Twitter and Pinterest. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.


News Article | November 7, 2016
Site: www.sciencedaily.com

Results of a cellular therapy clinical trial for traumatic brain injury (TBI) using a patient's own stem cells showed that the therapy appears to dampen the body's neuroinflammatory response to trauma and preserve brain tissue, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results, which also confirmed safety and feasibility as cited in earlier studies, were published online Nov. 1 in the journal STEM CELLS. "The data derived from this trial moves beyond just testing safety of this approach," said Charles S. Cox, Jr., M.D., principal investigator, the George and Cynthia Mitchell Distinguished Chair in Neurosciences at UTHealth, professor in the Department of Pediatric Surgery and co-director of the Memorial Hermann Red Duke Trauma Institute. "We now have a hint of a treatment effect that mirrors our pre-clinical work, and we are now pursuing this approach in a Phase 2b clinical trial sponsored by the Joint Warfighter Program within the U.S. Army Medical Research Acquisition Activity, as well as our ongoing Phase 2b pediatric severe TBI clinical trial -- both using the same autologous cell therapy." Cox was recently awarded $6.8 million in funding from the U.S. Department of Defense (DOD) for the Phase 2b study to assess the safety and efficacy -- including whether there are structural improvements in the brain -- of autologous stem cell therapy in adults with emergent traumatic brain injury. Memorial Hermann-Texas Medical Center is the site for the study. According to the Centers for Disease Control, 1.7 million Americans sustain a traumatic brain injury annually. Of those, 275,000 are hospitalized and 52,000 die. TBI is a contributing factor to a third of all injury-related deaths in the country. According to published research cited in the paper, more than 6.5 million patients are burdened by the physical, cognitive and psychosocial deficits associated with TBI, leading to an economic impact of approximately $60 billion. There are few current therapies to treat TBI. Critical care teams work to stabilize patients and surgery is sometimes necessary to remove or repair damaged blood vessels or tissue, as well as provide relief from swelling. To potentially open a new avenue of treatment, Cox has been researching cell therapy for neurological disease in pre-clinical and clinical trials for more than two decades. The new study builds on his previously published research showing that autologous stem cell therapy after TBI is safe and reduces the therapeutic intensity requirements of neurocritical care. The theory is that the stem cells work in the brain to alleviate the body's inflammatory response to the trauma. Researchers enrolled 25 patients in a dose-escalation format with five controls followed by five patients in each of three different doses followed by five more controls for a total of 25. Bone marrow harvesting, cell processing and re-infusion occurred within 48 hours after injury. Cellular processing was done at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at McGovern Medical School. Functional and neurocognitive outcomes were measured and correlated with imaging data including magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) of white brain matter. According to the authors, despite the treatment group having greater injury severity, there was structural preservation of critical regions of interest that correlated with functional outcomes and key inflammatory cytokines were down-regulated after bone marrow cell infusion.


News Article | February 15, 2017
Site: www.PR.com

Charlottesville, VA and Oakbrook Terrace, IL, February 15, 2017 --( In the past, pediatric surgeon authors would spend hours recording their knowledge and expertise in book chapters that were published once a decade by commercial publishers. The Pediatric Surgery Library was created as an alternative - to be current, affordable, and accessible on any device. A visionary team of APSA leaders working with experts from Unbound Medicine developed a new approach to encoding and disseminating pediatric surgical knowledge. More than 400 APSA member surgeons now author evidence-based, multi-faceted content in uPub™ - Unbound’s online authoring and content management system. After online editing and approval by an editorial board, the content is published instantaneously worldwide - to smartphone and tablet Apps as well as to a full-featured website. "APSA leadership and member surgeons yearned for a way to deliver pediatric surgical knowledge in a just-in-time fashion," said David Powell, MD, Co-Editor and Clinical Professor of Surgery at Stanford University. "Leveraging APSA member expertise, adult learning theory, and Unbound’s end-to-end platform we developed the resource our members wanted in record time." Updated regularly, the Pediatric Surgery Library is structured by learning objectives and is augmented by surgical images, videos, and links to Maintenance of Certification CME and the medical literature. Native Apps for Apple and Android device are fully integrated with the "The vision we share with APSA is to help trainees and practitioners answer clinical questions wherever they arise," says Bill Detmer, MD, president of Unbound Medicine. "We are excited to publish the work of APSA surgeons who do a remarkable job as educators and providers of advanced care for infants and children." About Unbound Medicine Unbound Medicine builds digital products that answer clinical questions at the point of need. With expertise in medical informatics, health technology, and medical publishing, our team has delivered innovative mobile and web solutions to health care institutions and individual clinicians for more than 15 years. Additional information is available at About the American Pediatric Surgical Association The American Pediatric Surgical Association is the nation’s largest professional organization dedicated to the pediatric surgical specialty. Since 1970 APSA has been dedicated to the development of the field of pediatric surgery to ensure the best care for the patients and families their membership serves. As an organization and in tandem with other groups, APSA sets guidelines and statements for standards of care for infants and children and for influencing public policy around the surgical care of children. Additional information is available at Contact Charlottesville, VA and Oakbrook Terrace, IL, February 15, 2017 --( PR.com )-- Unbound Medicine , a leader in knowledge management solutions for health care, and the American Pediatric Surgical Association (APSA), the nation’s largest professional organization serving the pediatric surgical specialty, today launched the Pediatric Surgery Library - the premier digital resource for pediatric surgical education, training, and research.In the past, pediatric surgeon authors would spend hours recording their knowledge and expertise in book chapters that were published once a decade by commercial publishers. The Pediatric Surgery Library was created as an alternative - to be current, affordable, and accessible on any device.A visionary team of APSA leaders working with experts from Unbound Medicine developed a new approach to encoding and disseminating pediatric surgical knowledge. More than 400 APSA member surgeons now author evidence-based, multi-faceted content in uPub™ - Unbound’s online authoring and content management system. After online editing and approval by an editorial board, the content is published instantaneously worldwide - to smartphone and tablet Apps as well as to a full-featured website."APSA leadership and member surgeons yearned for a way to deliver pediatric surgical knowledge in a just-in-time fashion," said David Powell, MD, Co-Editor and Clinical Professor of Surgery at Stanford University. "Leveraging APSA member expertise, adult learning theory, and Unbound’s end-to-end platform we developed the resource our members wanted in record time."Updated regularly, the Pediatric Surgery Library is structured by learning objectives and is augmented by surgical images, videos, and links to Maintenance of Certification CME and the medical literature. Native Apps for Apple and Android device are fully integrated with the PedSurgLibrary.com website and both are available for one price for individual users and institutional site-license customers."The vision we share with APSA is to help trainees and practitioners answer clinical questions wherever they arise," says Bill Detmer, MD, president of Unbound Medicine. "We are excited to publish the work of APSA surgeons who do a remarkable job as educators and providers of advanced care for infants and children."About Unbound MedicineUnbound Medicine builds digital products that answer clinical questions at the point of need. With expertise in medical informatics, health technology, and medical publishing, our team has delivered innovative mobile and web solutions to health care institutions and individual clinicians for more than 15 years. Additional information is available at www.unboundmedicine.com About the American Pediatric Surgical AssociationThe American Pediatric Surgical Association is the nation’s largest professional organization dedicated to the pediatric surgical specialty. Since 1970 APSA has been dedicated to the development of the field of pediatric surgery to ensure the best care for the patients and families their membership serves. As an organization and in tandem with other groups, APSA sets guidelines and statements for standards of care for infants and children and for influencing public policy around the surgical care of children. Additional information is available at www.eapsa.org Contact sales@unboundmedicine.com for information regarding institutional-wide access. Click here to view the list of recent Press Releases from Unbound Medicine

Loading Pediatric Surgery collaborators
Loading Pediatric Surgery collaborators